WHAT THIS STUDY ADDS
In our patients, determinations of serum levels of micafungin were
performed and 100% of the levels exceeded the threshold of 0.25 mg/L,
regardless of age, weight, administered dose, albumin levels,
creatinine and the presence or absence of graft-versus-host disease
(GVHD).
The poor interaction of micafungin with other drugs, its safety
profile and the administration on alternating days suggest a decrease
in toxicity and days of hospitalization, especially for patients with
SCD, without an increase in breakthrough on alternating days in
pediatric patients.